Omeros Corporation's stock surges as narsoplimab data shows 68% lower death risk in HSCT-TMA patients. Click to learn about the potential and risks of OMER stock.

A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) ...

Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

In other recent news, Omeros Corporation has announced promising results from its investigational drug, narsoplimab, in reducing mortality for patients with thrombotic microangiopathy (TA-TMA ...

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. In fact, according ...